Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
- Revenue in USD (TTM)8.70bn
- Net income in USD3.27bn
- Incorporated1989
- Employees3.90k
- LocationVertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Mergers & acquisitions
| Acquired company | VRTX:NSQ since announced | Transaction value |
|---|---|---|
| ViaCyte Inc | 3.54% | 320.00m |
| Catalyst Biosciences Inc-Complement Portfolio | 17.83% | 60.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 43.37bn | 85.00k | 38.00 | 8.11 | 19.47 | 3.03 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.16 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| Moderna Inc | 21.39bn | 11.77bn | 66.96bn | 2.70k | 6.30 | 3.75 | 5.53 | 3.13 | 27.65 | 27.65 | 50.69 | 46.49 | 0.9106 | 2.93 | 7.33 | 7,922,222.00 | 50.09 | 41.17 | 77.88 | 66.78 | 79.20 | -- | 55.00 | 52.35 | 1.80 | -- | 0.0599 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| Zoetis Inc | 8.01bn | 2.07bn | 78.21bn | 12.10k | 38.35 | 16.79 | 30.95 | 9.77 | 4.38 | 4.38 | 16.94 | 10.00 | 0.5849 | 1.14 | 6.84 | 661,735.60 | 15.08 | 13.79 | 17.93 | 16.04 | 70.19 | 68.75 | 25.78 | 23.94 | 1.48 | 12.19 | 0.5847 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Vertex Pharmaceuticals Incorporated | 8.70bn | 3.27bn | 81.44bn | 3.90k | 25.04 | 6.25 | 23.83 | 9.36 | 12.67 | 12.67 | 33.69 | 50.77 | 0.5934 | 2.89 | 7.00 | 2,230,913.00 | 22.32 | 18.01 | 26.40 | 21.87 | 88.00 | 87.77 | 37.62 | 29.17 | 4.55 | 32.16 | 0.0328 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Regeneron Pharmaceuticals Inc | 13.71bn | 5.37bn | 82.55bn | 10.37k | 15.99 | 3.85 | 14.48 | 6.02 | 47.40 | 47.40 | 120.98 | 197.05 | 0.534 | 0.8967 | 2.49 | 1,322,357.00 | 20.92 | 25.64 | 24.00 | 29.99 | 85.39 | 88.51 | 39.17 | 39.11 | 4.52 | 20.54 | 0.1119 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Gilead Sciences, Inc. | 27.14bn | 3.33bn | 105.36bn | 14.40k | 31.77 | 5.00 | 19.44 | 3.88 | 2.64 | 2.64 | 21.52 | 16.81 | 0.4186 | 4.39 | 6.08 | 1,884,445.00 | 5.10 | 8.35 | 6.07 | 10.02 | 74.62 | 79.56 | 12.19 | 22.22 | 1.16 | 5.86 | 0.545 | 58.76 | 10.60 | -2.12 | 4,960.98 | -14.34 | -4.99 | 9.07 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 20.07m | 7.82% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 16.09m | 6.27% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2022 | 15.67m | 6.11% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2022 | 12.52m | 4.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 12.29m | 4.79% |
| AllianceBernstein LPas of 30 Sep 2022 | 9.15m | 3.56% |
| Wellington Management Co. LLPas of 30 Sep 2022 | 8.03m | 3.13% |
| Geode Capital Management LLCas of 30 Sep 2022 | 5.27m | 2.05% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2022 | 5.16m | 2.01% |
| Jennison Associates LLCas of 30 Sep 2022 | 4.76m | 1.85% |
